Evidence map›Paper›PMID 40242062›Full record

ArticleOpen forum infectious diseases2025

Infective Endocarditis in People Who Inject Drugs-A 5-Year Follow-up: "I've Seen the Needle and the Damage Done".

Mika Halavaara, Veli-Jukka Anttila, Asko Järvinen

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mika HalavaaraDepartment of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0003-4752-0209
Veli-Jukka AnttilaDepartment of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0001-7734-9241
Asko JärvinenDepartment of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1906-7665

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infective endocarditis (IE) among people who inject drugs (PWID) has been associated with better short-term outcome. Long-term outcome of PWID with IE is poorly known. Methods: This retrospective population-based study included PWID with IE and non-PWID adults with community-acquired IE who were diagnosed and treated in Southern Finland between 2013 and 2017 and survived the initial IE episode. All patients were followed for 5 years. Data were collected on drug use, receipt of medications for opioid use disorder (MOUD), survival, and subsequent IE episode during follow-up. Results: Seventy-five PWID with IE and 98 patients with community-acquired IE were included. Buprenorphine and amphetamine or other stimulant were the most used substances among PWID. Sixteen PWID received MOUD before onset of IE, and 33 received MOUD at the time of discharge. Most PWID (86%) received addiction specialist consultation during the hospitalization. Fifteen patients in the PWID IE group experienced a new IE episode within 5-year follow-up as compared with 5 patients in the non-PWID IE group (odds ratio [OR], 4.65; Conclusions: Long-term survival of PWID with IE is poor, and they are at increased risk of a new IE episode as compared with non-PWID with community-acquired IE. More efforts in the treatment of addiction are needed.

Indexed as

addiction treatmentendocarditis outcomeinfective endocarditisintravenous drug usepersons who inject drugs

Identifiers

PMID40242062
PMCPMC12001338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.